The Pharmaceutical Journal, June 18, 2015

Malini Guha 

In his laboratory at the Beth Israel Deaconess Medical Center in Boston, Massachusetts, Harvard professor Vikas Sukhatme has identified several surface markers found on a type of immune cell called a myeloid-derived suppressor cell (MDSC).

March 2015

Northwestern Mutual Wealth Management Advisor Steve Braun recently received a 2015 Community Service Award as the Most Exceptional Volunteer for his work with Cures Within Reach.  Learn about our Executive Board member, Steve Braun, and his efforts to support our growth.  Steve Braun's Community Involvement

 

 

Part II: Business Review

Drug Discovery World, Spring 2015

Dr. Stephen Naylor, David M. Kauppi and Judge M. Schonfeld

There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable.The activity and productivity of DRPx focused companies as well as pharmaceutical company efforts appear to offer some encouragement in providing solutions to the myriad of problems the industry faces at the present time.These efforts can only be sustained and expanded if the dynamic variables of viable and creative business models are identified and understood. In this work we describe the lessons that can be learnt from surveying the landscape of the DRPx industry.This analysis includes both the successes and the failures of past DRPx companies.We introduce the various stakeholders that are shifting the decision process of DRPx implementation and acceptance away from the pharmaceutical industry. In addition the component pieces necessary to enhance the value of a DRPx company are discussed and the top 10 mini- blockbuster and blockbuster DRPx drugs are introduced. Finally, we assess and compare an assortment of DRPx business models and evaluate the current climate of the DRPx industry.

Read Full Article Here

MILWAUKEE, March 11, 2015 PRNewswire

Whether it's becoming a Big Brother, setting up a lemonade stand or advocating for economic and social equality for women and girls, Northwestern Mutual financial representatives are actively involved in their communities. To recognize this, Northwestern Mutual, through its foundation, is awarding financial representatives with the company's 2015 Community Service Award.

Three winners in each of the four regions will receive a $15,000 or $20,000 grant for their nonprofit, while an additional winner per region is named most exceptional, earning $25,000 for their organization. In total, the foundation is awarding $285,000 in grants.

"Each year I'm overwhelmed by the outstanding work our financial representatives are doing in their communities and their strong spirit of giving is echoed across our company each day," said John Kordsmeier, president, Northwestern Mutual Foundation. "The impact of these individuals extends our business and reaches the heart of what we do every day by putting others first."

Drug Discovery World

Dr. Stephen Naylor & Judge M. Schonfeld, Winter 2014

The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous generic drug sector, and patients that have morphed into a discerning consumer population.

The growing interest, activity and productivity in Drug Repurposing, Drug Repositioning and Drug Rescue (DRPx) appears to offer some encouragement in finding solutions to the myriad of problems the pharmaceutical companies must overcome. Here we describe the current status of DRPx, discuss the emerging consensus on terminology and describe the tools, technologies and approaches utilised in DRPx. 

Read full article here

How We Get To Next 

Nick Sireau, September 29, 2014

NickSireauBruce Bloom is just one man, but he potentially knows a way to save millions of lives. Addressing a room full of pharma executives at a conference in Boston, he commands their full attention. He speaks with authority and passion.The topic is one that industry has shirked for too long. It’s about how to find new purposes for existing drugs when there’s no intellectual property left to protect. Most of us don’t realize that many of the drugs we rely upon regularly can be used for many different, often unrelated, illnesses...

                                            Read full article here 

DiscoverMagDiscover Magazine

Carolyn Graybeal, August 22, 2014

Each year in the U.S. millions of dollars' worth of useable medication is destroyed. While at the same time one in four working adults cannot afford their medication. It is a confusing and unnecessary contradiction.
Fortunately innovative organizations recognize that by recycling or repurposing medication it is possible to limit waste and conserve resources while helping individuals live healthier lives.

Full Article

June 18, 2014

New web portal, built in collaboration with GlobalCures, will accelerate the open medical research approach to discover affordable, effective repurposed therapies

Marquette Intellectual Property Review, Volume 18, Issue 1 (2014)

Dr. Bruce Bloom

The current medical solution industry, with amazing scientists and businesspeople working as hard as they can, is not creating treatments and cures for most of the world's diseases. Pharma in 2013 is using a fifty-year-old business model to leverage current knowledge and technology, but that is generating few new treatments, and each treatment increases healthcare costs.  Read More

 

HealthlineNews

by Shawn Radcliffe, January 14, 2014

Copy of drugsResearchers are testing existing drugs and compounds as they search for new cancer treatments hidden in plain site.

Blood pressure medications, antidepressants, antipsychotics: these may seem like unlikely cancer fighters, but in the search for effective new treatments, researchers are casting a wider net in hopes of finding existing compounds that improve patients' chances of survival.
In addition to providing alternative treatments, repurposed—or repositioned—drugs, as they are called, can also help researchers understand how a particular disease works or identify new molecular targets that can lead to even more effective drugs.  Read full article here

Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases

Repurposing has the objective of targeting existing drugs and failed, abandoned, or yet-to-be-pursued clinical candidates to new disease areas. The open-source model permits for the sharing of data, resources, compounds, clinical molecules, small libraries, and screening platforms to cost-effectively advance old drugs and/or candidates into clinical re-development. Clearly, at the core of drug-repurposing activities is collaboration, in many cases progressing beyond the open sharing of resources, technology, and intellectual property, to the sharing of facilities and joint program development to foster drug-repurposing human-capacity development. A variety of initiatives under way for drug repurposing, including those targeting rare and neglected diseases, are discussed in this review and provide insight into the stakeholders engaged in drug-repurposing discovery, the models of collaboration used, the intellectual property-management policies crafted, and human capacity developed. Read full article 

FierceBiotech November 2013

FailedDrugsThe true cost of drugs that fail in clinical trials should be measured by far more than the cash poured into the development process. Everyone loses something, whether it be the patients who are waiting for new treatments or the companies losing resources that could have gone back into bolstering R&D.

Some of the investment into these failed or shelved drugs can be recouped by giving them a second and often lower-risk chance in a new indication. This is known as drug repositioning, drug repurposing or drug rescue. It may be carried out by the company that invented the drug, but it’s more commonly pursued these days by smaller, more specialized companies.  

Read more

Rediscovery More for Less

ebr July 2013Dr. Bruce Bloom, July 2013

Conducting medical research for drug rediscovery is a growing challenge, as the amount that is spent on it is minimal. However, there are many advantages with this method that are being overlooked See full article here

Sign up for our eNewsletter today!

 

First Name




Search

Cures Within Reach

Illinois Science+Technology Park

8025 Lamon Avenue, Suite 440

Skokie, IL 60077

(847)745-1252

info@cureswithinreach.org

 

Friday the 21st. copyright 2015 Cures Within Reach.